FineMark National Bank & Trust’s Alnylam Pharmaceuticals ALNY Stock Holding History

FineMark National Bank & Trust’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-37	Closed	-$3K	–	1343
2015 Q3	$3K	Buy	+37	New	+$4.11K	﹤0.01%	1159
2014 Q4	–	Sell	-22	Closed	-$2K	–	1406
2014 Q3	$2K	Hold	22	–	–	﹤0.01%	1238
2014 Q2	$1K	Buy	22 +4	+22%	+$238	﹤0.01%	1320
2014 Q1	$1K	Buy	18 +9	+100%	+$697	﹤0.01%	1338
2013 Q4	$1K	Buy	+9	New	+$537	﹤0.01%	1401

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

FineMark National Bank & Trust's ALNY Position: Q4 2015 in Review

FineMark National Bank & Trust sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2015, closing a stake of 37 shares — an estimated $3K sold.

FineMark National Bank & Trust first reported a position in ALNY in Q4 2013 and held it in 5 quarters. The position peaked at $3K in Q3 2015. 261 funds tracked by Wall St. Rank hold ALNY as of Q4 2015.

FineMark National Bank & Trust reported no remaining Alnylam Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
FineMark National Bank & Trust sold 37 Alnylam Pharmaceuticals shares in Q4 2015, an estimated $3K.
FineMark National Bank & Trust first reported a position in Alnylam Pharmaceuticals in Q4 2013 and held it in 5 quarters.
FineMark National Bank & Trust's Alnylam Pharmaceuticals position peaked at $3K in Q3 2015.
261 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2015.

Based on FineMark National Bank & Trust's 13F filing for Q4 2015, filed 9 Feb 2016.